Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Drug

AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested

Fineline Cube Apr 24, 2026
Company Deals

Chipsscreen Biosciences and Zhejiang Hisun Pharmaceutical End Strategic Partnership for Chiglitazar Launch

Fineline Cube Oct 31, 2024

China-based Chipscreen Biosciences Co., Ltd (SHA: 688321) has reached an agreement with Zhejiang Hisun Pharmaceutical...

Company

Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound

Fineline Cube Oct 31, 2024

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has reported its financial results for...

Company

AstraZeneca China President Leon Wang Involved in Chinese Investigation Amid Industry Probes

Fineline Cube Oct 31, 2024

Leon Wang, Executive Vice President International and AstraZeneca (AZ, NASDAQ: AZN) China President, is cooperating...

Company Drug

AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China

Fineline Cube Oct 31, 2024

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of...

Company Deals Medical Device

Jiangsu Yuyue Medical Equipment Partners with TÜV SUD to Boost Medical Device Market Access

Fineline Cube Oct 31, 2024

Jiangsu Yuyue Medical Equipment Inc., (SHE: 002223), a Chinese medical equipment manufacturer, has entered into...

Company

GSK Reports Mixed Q3 2024 Results with 2% YOY Revenue Growth

Fineline Cube Oct 31, 2024

UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third...

Company Deals

Allmed Medical Products to Establish Wholly Owned Subsidiary in Indonesia

Fineline Cube Oct 31, 2024

China-based Allmed Medical Products Co., Ltd (SHE: 002950) has announced plans to establish a wholly...

Company Drug

Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Files for New Indication with China’s NMPA

Fineline Cube Oct 31, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that the National Medical Products Administration...

Company Drug

Akeso Biopharma Initiates Phase III Clinical Trial for PD-1/VEGF Bispecific Antibody Combination

Fineline Cube Oct 31, 2024

China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first patient in a...

Company

AbbVie Reports Q3 2024 Revenue Growth, Strength in Immunology and Neuroscience

Fineline Cube Oct 31, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has announced its financial results for the third quarter...

Company Drug

Shanghai Henlius and Organon Submit Biosimilar Application for Denosumab to FDA

Fineline Cube Oct 31, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) and its US partner Organon (NYSE: OGN) have jointly...

Company

Pfizer Reports Strong Q3 Results, Boosts 2024 Guidance to $61-$64 Billion

Fineline Cube Oct 30, 2024

Pfizer Inc. (NYSE: PFE) released its Q3 2024 financial results, reporting revenues of $17.702 billion...

Company Drug

AIM Vaccine Secures NMPA Approval for mRNA Vaccine Targeting RSV

Fineline Cube Oct 30, 2024

AIM Vaccine Co., Ltd (HKG: 6660), based in China, has received clinical trial approval from...

Company Medical Device

Acotec Secures NMPA Approval for Acotrace Disposable Catheter Sheath

Fineline Cube Oct 30, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), based in China, has received marketing approval from the...

Company Deals

Innovent’s Fortvita Stake Sale Sparks Controversy, Shares Plummet Nearly 13%

Fineline Cube Oct 30, 2024

Innovent Biologics, Inc. (HKG: 1801), headquartered in China, has announced a subscription agreement in which...

Company Medical Device

Sino Medical Reports Five-Year PIONEER Study Results for HT Supreme Stent System

Fineline Cube Oct 30, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), based in China, has announced the five-year follow-up...

Company Drug

Novartis Secures FDA Accelerated Approval for Scemblix in Newly Diagnosed CML Patients

Fineline Cube Oct 30, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its drug Scemblix (asciminib) has received accelerated...

Company Deals

MGI Tech Partners with OncoDNA to Enhance Precision Oncology Solutions

Fineline Cube Oct 30, 2024

MGI Tech Co., Ltd., (SHA: 688114) a China-based leader in gene sequencing, announced a strategic...

Company Medical Device

Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges

Fineline Cube Oct 30, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing...

Company

BeiGene CCO Yin Min Detained Amid Investigation; Company Affirms Compliance Standards

Fineline Cube Oct 30, 2024

On October 25, Yin Min, Chief Commercial Officer of BeiGene (NASDAQ: BGNE) Greater China, was...

Posts pagination

1 … 266 267 268 … 656

Recent updates

  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
  • Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction
  • Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market
  • China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Company Medical Device

Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction

Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.